（本网讯）8月13日，加拿大海洋生物技术公司（Oceanix Biotechnology Corporation）在BC省三角洲市隆重开业，加拿大就业、劳动力发展暨残疾人安置部部长卡拉·奎尔特罗（Carla Qualtrough）和加拿大海洋生物技术公司总裁兼执行长马哈茂德·阿齐兹（Mahmoud S. Aziz）为公司开业剪彩。
(News from this website) On August 13, Oceanix Biotechnology Corporation grandly opened in Delta City, BC. Carla Qualtrough, Minister of Employment, Workforce Development and Disability Placement of Canada, and Mahmoud S. Aziz, President and CEO of Canadian Oceanix Biotechnology Corporation, cut the ribbon for the company's opening.
上图左二为奎尔特罗部长，左三为阿齐兹总裁。
The second from left in the picture above is Minister Qualtrough, and the third from left is President Aziz.
海洋生物技术公司是一家领先的，加拿大创新生物技术和生物制药公司积极参与全球海洋生物技术和生物制药行业，是全球最大的可持续锁孔帽贝血蓝蛋白（KLH）和KLH蛋白生产商，也是加拿大唯一的一家生产商，用于全球抗癌疫苗和免疫治疗行业。
Oceanix Biotechnology Corp. is a leading, innovative Canadian biotechnology and biopharmaceutical company that actively participates in the global marine biotechnology and biopharmaceutical industry, and is the world’s largest producer of sustainable keyhole limpet hemocyanin (KLH) and KLH proteins. It is also the only manufacturer in Canada for the global anti-cancer vaccine and immunotherapy industries.
奎尔特罗部长祝贺公司正式开业，她高度赞扬公司克服重重困难，特别是在新冠疫情肆虐期间，也没有停止工作，为推动加拿大经济发展，增加就业机会作出了积极贡献。
Minister Qualtrough congratulated the company for its official opening. She highly praised the company for overcoming many difficulties, especially during the period of the epidemic of Covid-19, all employees did not stop working, and made positive contributions to promoting Canadian economic development and increasing employment opportunities.
阿齐兹总裁介绍说，海洋生物技术公司初创于2015年，经过长达六年的准备工作，公司终于在今天正式开业。公司不仅在加拿大，还在中国和菲律宾开展业务，积极参与海洋和海洋环境的勘探，寻找海洋和海洋生物量的新来源和供应，寻找潜在的生物制药和药物化合物，并且还从事海洋生物的可持续水产养殖，以及利用生态稳定和可持续的海洋和海洋生物资源（生物质）研发和商业化新型药物、生物药物、营养食品和OTC产品。该公司探索加拿大和全球海洋生态系统的多样性，开发和销售新的生物医学、营养和食品产品和技术，这些产品和技术只能从海洋生物中发现的独特形式、结构、生理和化学中获得。该公司的主要目标是在加拿大、中国和其他国家创造高附加值产业，利用可持续的本地海洋生物量开发新分子/生物活性化合物的一致生产、提取、纯化和商业化过程。
President Aziz said that Oceanix was founded in 2015. After six years of preparation, the company finally officially opened today. The company is not only doing business in Canada, but also in China and the Philippines, actively participating in the exploration of the ocean and marine environment, looking for new sources and supplies of marine and marine biomass, looking for potential biopharmaceuticals and pharmaceutical compounds, and also engaged in the potential of marine organisms. Continuous aquaculture, and the use of ecologically stable and sustainable marine and marine biological resources (biomass) to develop and commercialize new drugs, biological drugs, nutritional foods and OTC products. The company explores the diversity of Canadian and global marine ecosystems, develops and markets new biomedical, nutritional and food products and technologies that can only be obtained from the unique forms, structures, physiology and chemistry found in marine organisms. The company's main goal is to create high-value-added industries in Canada, China and other countries, using sustainable local marine biomass to develop consistent production, extraction, purification and commercialization processes for new molecules/bioactive compounds.
上图左一为孟为建副总裁。
The first on the left is Vice President Meng Weijian.
该公司董事副总裁孟为建（Nicholas Mang）介绍说，公司有位投资者是来自中国南京的移民，因此，我们在南京有办公室也有工厂。同时，公司不仅在加拿大与渔业和海洋中心水产养殖和环境研究中心（CAER）、加拿大国家研究委员会（NRC），而且和中国青岛的中国海洋大学有联合研究和开发合作。公司的主要项目就是今天开张的BC省三角洲市的研发和制造工厂，投资2000万美元的KLH蛋白质制造项目，涉及巨型锁孔帽贝软体动物的可持续商业养殖以及药物级血蓝蛋白（KLH 1、KLH 2、，KLH 3），作为抗癌药物和免疫治疗的佐剂——全球生物制药行业增长最快的领域之一。该公司还正在研究和开发利用各种外来红藻、海兔排泄物和水葫芦制成的新型抗癌药物，以及利用海参制成的新型生物药物，以及利用各种藻类制成的新型营养食品和功能食品。
According to Nicholas Mang, the vice president of the company's board of directors, one of the company's investors is an immigrant from Nanjing, China. Therefore, we have an office and a factory in Nanjing. At the same time, the company not only has joint research and development cooperation with the Fisheries and Ocean Center Aquaculture and Environmental Research Center (CAER) and the Canadian National Research Council (NRC) in Canada, but also has joint research and development cooperation with Ocean University of China in Qingdao, China. The company’s main project is the R&D and manufacturing plant in Delta, BC, which opened today. The KLH protein manufacturing project with an investment of 20 million US dollars involves the sustainable commercial breeding of giant keyhole mollusks and pharmaceutical-grade hemocyanin (KLH 1 , KLH 2, KLH 3), as an adjuvant for anti-cancer drugs and immunotherapy-one of the fastest growing fields in the global biopharmaceutical industry. The company is also researching and developing new anti-cancer drugs made from various exotic red algae, sea hare excrement and water hyacinth, new biological drugs made from sea cucumbers, and new nutritious foods and functional foods made from various algae.
上图为阿扎德博士。
The picture above shows Dr. Azad
该公司研究室主任卡拉姆·阿扎德博士（Dr. Kalam Azad）带领我们参观了公司养殖车间，他告诉我们，公司已成功地对几种海洋生物进行了分类，这些生物在全细胞或分子水平上具有关键治疗特性，对医疗保健、化妆品、生物修复、制药、营养食品和功能性食品等主要行业有重大影响。利用现代分子生物学、基因工程和细胞科学的最新突破，我们能够提供必要的基础设施，成功提取、表征、分离和纯化这些关键生物分子，将创新产品、技术和工艺推向全球市场，主要在生物医学和制药领域。该公司严格确保其来自加拿大和全球的海洋和海洋生物资源供应链生态稳定和可持续，并参与这些海洋和海洋生物的陆上水产养殖，以支持和确保稳定和一致的供应，防止脆弱生态系统的生态退化。
Dr. Kalam Azad, the director of the company’s research centre, led us visit the company’s breeding workshop. He told us that the company has successfully classified several marine organisms. These organisms are in whole cells or molecules. It has key therapeutic properties at the level and has a significant impact on major industries such as healthcare, cosmetics, bioremediation, pharmaceuticals, nutraceuticals, and functional foods. Utilizing the latest breakthroughs in modern molecular biology, genetic engineering and cell science, we can provide the necessary infrastructure to successfully extract, characterize, isolate and purify these key biomolecules, and bring innovative products, technologies and processes to the global market, mainly in Biomedical and pharmaceutical fields. The company strictly ensures that its supply chain of marine and marine biological resources from Canada and the world is ecologically stable and sustainable, and participates in the land-based aquaculture of these marine and marine life to support and ensure stable and consistent supply and prevent fragile ecosystems Ecological degradation.
在访谈中，阿齐兹总裁说，他曾在中国的北京、深圳、西安等城市工作过，对中国又很深的了解，所以，公司不仅在南京建厂，还将在厦门建厂，而且规模都比在加拿大本土的工厂大得多。阿齐兹总裁也是加拿大拥有的CANAGEN制药公司（Canagen Pharmaceuticals Inc.）的总裁兼执行长，而今天开张的海洋生物技术公司是CANAGEN制药公司的子公司。CANAGEN制药公司是一家成熟的创新型跨国制药公司，积极从事成品药、仿制药、活性药物成分（API）和OTC产品的生产以及研究，开发和商业化涵盖心血管、肿瘤、痴呆和抗病毒治疗领域的新药。CANAGEN的营养食品部门积极参与创新营养食品的研究、开发和商业化，利用最佳制药实践。同时，CANAGEN在加拿大、中国、印度和俄罗斯拥有并运营着十家经认证的GMP制药厂，并在加拿大、印度和中国拥有专门的研发设施。
In the interview, President Aziz said that he had worked in Beijing, Shenzhen, Xi'an and other cities in China, and had a deep understanding of China. Therefore, the company will not only build a factory in Nanjing, but also build a factory in Xiamen. The scale will be much larger than the factory in Canada. President Aziz is also the President and CEO of Canada-owned Canagen Pharmaceuticals Inc., and Oceanix that opened today is a subsidiary of Canagen. Canagen is a mature and innovative multinational pharmaceutical company, actively engaged in the production and research, development and commercialization of finished drugs, generic drugs, active pharmaceutical ingredients (API) and OTC products, covering cardiovascular, tumor, dementia and anti-inflammatory drugs. New drugs in the field of virus therapy. Canagen’s Nutritional Food Division is actively involved in the research, development and commercialization of innovative nutritious foods, using best pharmaceutical practices. At the same time, Canagen owns and operates ten certified GMP pharmaceutical factories in Canada, China, India and Russia, and has specialized R&D facilities in Canada, India and China.
